California policy makers are being asked to support the resurgence of a past failed and dangerous psychiatric-psychedelic drug practice that went from a research lab to the couch to the streets, to the CIA and now back again to the lab, to again put patients at risk.
California legislators are considering passing a law, SB 519 that will legalize possession of psychedelic drugs and promote researching the mind-altering chemicals as treatment for “mental illness.”
This bill would make lawful the possession for personal use of psilocybin, psilocyn, dimethyltryptamine (DMT), ibogaine, mescaline, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA).
It stands to reason that for the market to reappear there’s profit to be made. The psychedelic “therapy” industry is predicted to reach $7 billion by 2027. Laws like the proposed California one will help make that target sooner, along with all the horrific side effects of these harmful and addictive drugs.
A petition that Citizens Commission on Human Rights Sacramento posted online opposes the bill, joining many others who disagree with it. CCHR International, the headquarters of which are based in Los Angeles, said the bill is part of a growing concern that psychiatrists’ failure to effectively treat substance abuse, addiction and mental problems can be helped by past failed “therapies.” The bill is dangerous to people’s mental health, given the known risks of these drugs.
Such research being resurrected today demonstrates a fundamental disregard for human life because of the drugs’ mind-altering properties, also borne out by the psychiatric-intelligence community’s past research of LSD, psilocybin and amphetamines.
CCHR suggests California legislators apprise themselves of past psychedelic drug research risks and prevent a re-occurrence of this failed and dangerous practice.